The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation
16 April 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced a successful $56 million Series C financing.
The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3, including funding the Company’s Phase 2 monotherapy study in selected sarcoma indications, in which the first patient has now been successfully dosed. Sarcoma is a form of cancer that arises in bone or soft tissues, including muscle, fat, cartilage, blood vessels, and other connective or supportive tissue. This study is designed to support a potential accelerated regulatory approval pathway for STC-15 and to establish a foundation for subsequent clinical development across additional oncology indications.
STORM’s sarcoma program builds on previous clinical and translational research in epitranscriptomic regulation, emphasizing the importance of RNA-modifying enzymes in the maintenance of stem cell‑derived tumors and their potential application in broader settings. METTL3 methylates mRNA, influencing the differentiation processes of connective tissues and other cell types. Sarcomas arise from transformed mesenchymal stem cells as they progress into malignant connective tissue cells, accounting for 1% of adult cancers and 15% of pediatric cancers. Due to the frequent absence of driver mutations or immunogenic features amenable to standard treatments, sarcomas depend on METTL3-driven methylation for growth and survival. The Phase 2 trial will assess the anti-tumor effects of inhibiting mRNA methylation in sarcomas.
The financing was funded by existing investors, M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI).
About STORM Therapeutics
STORM Therapeutics is a clinical-stage biotechnology company targeting RNA modifications to reprogram malignant cells and treat disease. STORM’s lead candidate, STC-15, is the first RNA-modifying enzyme inhibitor to enter human clinical trials. STC-15 specifically inhibits METTL3, an RNA-modifying enzyme that regulates stem cell transformation and differentiation, a critical process in the development of sarcomas and other tumors. STC-15 is currently being assessed as a monotherapy in a Phase 2 study for select sarcomas. Further information is available at www.clinicaltrials.gov NCT identifiers: NCT06975293.
